ANVA Publishing Corporation
ANVA Biologica
Volume 2026, Article ID AB1104

Review Article

FOXO1, AdipoR Signaling, and JAK/STAT3-Driven Renal Fibrosis: Molecular Nodes of a Unified Neuroendocrine–Metabolic Axis in Type 2 Diabetes Mellitus

S Charu Krishna Priya[1], Rishita Bandla[1]

[1]*Department of Microbiology, Garden City University, Bengaluru, India*
Correspondence should be addressed to charukrishna482@gmail.com

Received 21 January 2026; Accepted 13 April 2026

Adipokine imbalance, increasing renal fibrosis, and dysregulated hepatic gluconeogenesis are three interrelated pillars of Type 2 Diabetes Mellitus (T2DM) pathogenesis. Common signaling nodes, such as FOXO1, AdipoR1/R2, and JAK/STAT3, that are researched separately but seldom taken into account within a cohesive mechanistic framework, are shared by the molecular mechanisms coordinating these events. The molecular biology of FOXO1-driven hepatic gluconeogenesis, GLP-1-mediated cAMP/PKA regulation of gluconeogenic programs, AdipoR-mediated AMPK activation in insulin sensitization, and JAK/STAT3 propagation of diabetic nephropathy are the topics of this review. We present a new idea called Molecular Convergence Nodes (MCNs), which are druggable intersections where several disease pathways converge and where pharmacological intervention may result in increased therapeutic effect. In conclusion, FOXO1, AdipoR, and STAT3 are actionable MCNs whose combined targeting may more successfully disrupt the pathological reinforcement loops of type 2 diabetes than existing single-target approaches. We present a research plan for the future that focuses on combination pharmacotherapy and MCN-based biomarker identification.

Keywords: FOXO1, AdipoR1/R2, AMPK, JAK/STAT3, hepatic gluconeogenesis, diabetic nephropathy, GLP-1, molecular convergence nodes, adiponectin, renal fibrosis.

1. Introduction: From Isolated Pathways to Convergent Molecular Nodes

The molecular biology of Type 2 Diabetes Mellitus (T2DM) is defined by a network of interconnected signaling cascades that function concurrently in several organ systems (1,2). Although decades of research have yielded impressive granular insights into individual pathways, such as the TGF-β/Smad pathway in renal fibrosis, the cAMP/PKA axis in glucagon action, or the IRS-1/PI3K/Akt cascade in insulin signaling, a persistent limitation of the field has been the tendency to study these cascades in organ-specific isolation (3–5). Despite being analytically tractable, this organ-centric viewpoint has led to a fragmented therapeutic landscape where medications intended to address one metabolic abnormality seldom avoid problems resulting from the others (6). Clinically, individuals with T2DM frequently present with multiple coexisting pathologies, including insulin resistance, chronic inflammation, hepatic steatosis, and diabetic nephropathy, all of which share common molecular determinants (7,8). Identifying molecular nodes that lie at the intersection of several pathogenic pathways may therefore provide opportunities for more effective

therapeutic strategies capable of simultaneously targeting multiple disease processes (9). In this review, we concentrate on three molecular nodes that are particularly relevant to T2DM: (1) FOXO1, a transcription factor at the intersection of insulin signaling, gluconeogenesis, and oxidative stress; (2) Adiponectin Receptors (AdipoR1/R2), transducers of adiponectin-mediated anti-inflammatory and insulin-sensitizing actions across the liver, skeletal muscle, and kidney; and (3) JAK/STAT3, a signaling hub that integrates cytokine, adipokine, and metabolic inputs to drive renal and hepatic inflammation (10–12). We refer to these as Molecular Convergence Nodes (MCNs) and propose that they represent high-value therapeutic targets for the next generation of T2DM interventions (13).

2. FOXO1: Transcriptional Master Regulator of Hepatic Gluconeogenesis

2.1 FOXO1 Structure, Function, and Regulation

Forkhead box transcription factor O1 (FOXO1) is a transcription factor that belongs to the FOXO family and is distinguished by its conserved 110-amino acid forkhead DNA-binding region (14). FOXO1 is constitutively expressed in the liver and is essential for connecting gluconeogenic gene transcription with food availability (15). During fasting, FOXO1 localizes to the nucleus and activates the promoters of the two rate-limiting enzymes of gluconeogenesis, PCK1 (encoding PEPCK) and G6PC (encoding G6Pase), when glucagon and cortisol levels rise and insulin levels decrease (16,17). FOXO1 is suppressed by insulin via a well-known phosphorylation pathway (18). IRS-1/2 tyrosine phosphorylation, recruitment and activation of PI3K, production of PIP_3, and activation of the serine/threonine kinase Akt (also known as PKB) are all consequences of insulin receptor activation (19). Three residues of FOXO1—Thr24, Ser256, and Ser319—are directly phosphorylated by Akt, generating docking sites for 14-3-3 chaperone proteins that facilitate cytoplasmic sequestration (20). The main insulin-dependent inhibition of hepatic gluconeogenesis is caused by the nuclear exclusion of FOXO1 (21).

2.2 FOXO1 in Selective Hepatic Insulin Resistance

The phenomenon of selective hepatic insulin resistance, in which the mTORC1-dependent pathway driving de novo lipogenesis (DNL) remains insulin-sensitive or even hyperactivated while the PI3K/Akt/FOXO1 axis governing gluconeogenesis becomes insulin-resistant, is a conceptually significant aspect of T2DM pathophysiology (22,23). The paradoxical coexistence of hyperglycemia (from uncontrolled gluconeogenesis) and hypertriglyceridemia (from elevated DNL) in insulin-resistant individuals can be explained by this selective resistance (24). Diacylglycerol (DAG) and ceramide buildup, produced by excess lipid flow, activate PKCε and PKCδ, respectively, which selectively phosphorylate IRS-1/IRS-2 at inhibitory serine residues (25,26). This compartmentalization of signaling is the molecular foundation of selective insulin resistance (27). While mTORC2/Akt2-mediated lipogenic signaling is mostly unaffected, PI3K/Akt/FOXO1 signaling is blocked (28). JNK activation brought on by ER stress offers another method for selective IRS phosphorylation (29). Thus, FOXO1 maintains gluconeogenic production in T2DM by remaining inappropriately nuclear (30).

2.3 GLP-1–cAMP–PKA Modulation of FOXO1 Activity

GLP-1 signaling research has revealed a new and therapeutically important pathway for FOXO1 control (31). Activation of the GLP-1 receptor (GLP-1R) increases intracellular cAMP and activates protein kinase A (PKA) by coupling to Gs proteins and adenylyl cyclase (32). Insulin production in pancreatic beta-cells is primarily driven by this cAMP/PKA axis (33). However, cAMP/PKA signaling has paradoxical effects in hepatocytes that express low levels of GLP-1R: while glucagon-driven cAMP activates FOXO1 via CREB/PGC-1α, GLP-1-derived cAMP has been shown to phosphorylate and activate SIK2 (salt-inducible kinase 2), which promotes CRTC2 phosphorylation and cytoplasmic sequestration, thereby indirectly lower PGC-1α expression and gluconeogenic output (34,35). Additionally, without the need for direct hepatic GLP-1R stimulation, centrally-derived GLP-1R activation in the hypothalamus affects hepatic FOXO1 activity through vagal afferent's (36). This brain-to-liver regulatory arc most likely involves paracrine signaling from portal macrophages (Kupffer cells) and nitric oxide synthase in hepatic stellate cells, resulting in an indirect but functionally significant pathway for CNS control of FOXO1-driven gluconeogenesis (37,38). The increased hepatic advantages of CNS-penetrant GLP-1RAs over peripheral-only treatments may be explained by an understanding of this central-to-hepatic FOXO1 axis (39,40).

3. Adiponectin Receptor Signaling: AMPK-Mediated Metabolic Protection

3.1 AdipoR1 and AdipoR2: Structural Biology and Tissue Distribution

The mechanism behind the pleiotropic metabolic effects of adiponectin was discovered in 2003 by the molecular cloning of adiponectin receptors (AdipoR1 and AdipoR2) (41). In contrast to G-protein-coupled

receptors, both receptors are seven-transmembrane domain proteins that mainly transduce signals via the adaptor protein APPL1 (adaptor protein containing PH domain, PTB domain, and leucine zipper motif 1) (42). APPL1 provides the molecular connection between adiponectin and its metabolic benefits by bridging receptor activation to downstream AMPK, PPARα, and p38 MAPK signaling (43). AdipoR1 is widely expressed, although it is most abundant in skeletal muscle, where it facilitates the absorption of glucose and the synthesis of glycogen through the translocation of AMPK and GLUT4 (44). AdipoR2 is mostly expressed in the liver, where it suppresses de novo lipogenesis and promotes fatty acid oxidation by activating PPARα (45). Podocytes, mesangial cells, and proximal tubular cells of the kidney express both AdipoR1 and AdipoR2, which mediate anti-inflammatory and anti-fibrotic actions (46). Tissue-specific pharmacological targeting is made possible by each receptor subtype's tissue-specific preponderance (47).

3.2 AMPK as the Effector Kinase of AdipoR Signaling

As a cellular fuel gauge, AMP-activated protein kinase (AMPK) is a highly conserved energy-sensing heterotrimeric kinase that is triggered by increases in the AMP:ATP ratio during an energy shortage (48). APPL1-mediated LKB1 activation, which phosphorylates and activates AMPK at Thr172, is triggered by AdipoR1/AdipoR2 activation (49). A wide range of metabolic reprogramming is triggered by activated AMPK: phosphorylation of HMGCR reduces cholesterol synthesis; phosphorylation and nuclear exclusion of TORC2 (CREB-regulated transcription coactivator 2) reduces PGC-1α and gluconeogenic gene expression; and inhibition of ACC (acetyl-CoA carboxylase) reduces malonyl-CoA and disinhibits CPT1, increasing mitochondrial fatty acid oxidation (50–52). Through SIRT1-dependent deacetylation and activation of PGC-1α (different from the transcriptional induction mentioned above), AMPK also promotes mitochondrial biogenesis, which is crucial for type 2 diabetes (53). This enhances mitochondrial function and lowers mitochondrial oxidative stress, which is linked to beta-cell dysfunction, hepatic lipotoxicity, and renal tubular injury (54,55). AdipoR-mediated AMPK activation is therefore a particularly valuable therapeutic node since it concurrently tackles insulin resistance, lipotoxicity, and mitochondrial dysfunction (56).

3.3 AdipoR Signaling in the Kidney

AdipoR1 and AdipoR2 both mediate the renoprotective actions of adiponectin (57). By suppressing RhoA and increasing nephrin production, AdipoR-AMPK signaling in podocytes maintains the actin cytoskeletal architecture of foot processes (58). Adiponectin inhibits ECM formation and TGF-β1 production in mesangial cells via blocking mTOR via AMPK (59). By increasing antioxidant enzymes (SOD2, catalase) and decreasing NADPH oxidase activity, AMPK activation in proximal tubular cells lowers oxidative stress (60). These protective inputs are eliminated in T2DM by hypoadiponectinemia, which results in renal AdipoR insufficiency, which speeds up tubular oxidative stress, mesangial enlargement, and podocyte damage (61). Notably, clinical investigations have demonstrated that SGLT2 inhibitors, which are now the first-line treatments for cardiorenal protection in type 2 diabetes, upregulate adiponectin levels, indicating that part of its renoprotective impact may be mediated through AdipoR pathway restoration (62). This mechanistic understanding makes direct AdipoR agonism a viable additive renoprotective tactic (63).

4. JAK/STAT3 Signaling: Inflammatory Driver of Diabetic Nephropathy

4.1 JAK/STAT3 Pathway Architecture in Renal Cells

A classic intracellular signaling mechanism for a variety of cytokines, including as IL-6, IL-10, leptin, oncostatin M, and interferon-γ, is the JAK/STAT3 signaling axis (64). Upon ligand interaction, JAK1, JAK2, and TYK2 in renal cells connect to cytokine receptor subunits and transphosphorylate one another (65). By phosphorylating STAT3 at Tyr705, activated JAKs cause dimerization, nuclear translocation, and binding to promoter regions that are sensitive to STAT3 (TTCNNNGAA) (66). TGF-β1, MCP-1 (CCL2), VEGF-A, fibronectin, collagen I/IV, and SOCS3 are among the kidney's STAT3 target genes; the latter creates a negative feedback loop by inhibiting JAK (67,68). The counterintuitive suppression of SOCS3 expression in the diabetic kidney permits unchecked JAK/STAT3 activation, potentially due to epigenetic silencing via DNMT3a-mediated promoter methylation (69). The principal JAK2 deactivation phosphatase, protein tyrosine phosphatase 1B (PTP1B), is inactivated by reactive oxygen species (ROS), which causes high hyperglycemia to independently activate JAK2 (70). Through RAGE, advanced glycation end products (AGEs) offer an extra activation input (71). Even after diabetic recovery, a persistent inflammatory state is created by the convergence of cytokine, glucose, and AGE signals on the JAK/STAT3 cascade (72).

4.2 STAT3 and Podocyte Apoptosis

DN progression is both characterized by and driven by podocyte loss (73). Podocytes cannot renew once they are gone, and the glomerular scarring that results is permanent (74). Through a number of mechanisms,

including transcriptional upregulation of pro-apoptotic members of the Bcl-2 family (Bax, Bak), suppression of the survival factor Bcl-xL, and induction of TRPC6, a transient receptor potential channel that mediates calcium influx and calcineurin/NFAT-driven podocyte dedifferentiation, $STAT_3$ promotes podocyte apoptosis (75–77). Additionally, $Smad_3$ is activated by $STAT_3$-driven TGF-β1 synthesis, which causes proteinuria by downregulating nephrin and synaptopodin, two essential structural proteins of the slit diaphragm (78). Adipokine signaling and $STAT_3$ in podocytes have a significant and little-known relationship (79). Leptin stimulates TGF-β1 production and death in podocytes by directly activating $STAT_3$ through the long form of the leptin receptor (LepRb) via $JAK_2/STAT_3$ (80). The hyperleptinemic condition of obesity-associated type 2 diabetes may serve as a persistent direct stimulus for podocyte $STAT_3$ activation, irrespective of systemic inflammation, because podocytes express LepRb (81). A new mechanistic target that has received little attention in DN research is the podocyte-intrinsic leptin-JAK/$STAT_3$-TGF-β1 loop (82).

4.3 JAK/$STAT_3$ and Tubulo-Interstitial Fibrosis

Long-term renal outcomes in type 2 diabetes are significantly influenced by tubulointerstitial fibrosis, which goes beyond glomerular damage (83). Tubular cells lose their epithelial identity (downregulating E-cadherin and zonula occludens-1) and gain mesenchymal traits (upregulating vimentin, α-SMA, and fibronectin) during the tubular epithelial-to-mesenchymal transition (EMT), which is facilitated by activated $STAT_3$ (84). Major makers of collagen I and III, EMT-derived interstitial myofibroblasts are responsible for the gradual interstitial fibrosis that damages the renal parenchyma and lowers GFR (85). Crucially, the hepatic and adipokine axis interact with JAK/$STAT_3$ in the kidney (86). Renal $STAT_3$ is strongly activated by IL-6, which is produced in excess by visceral adipose tissue and inflammatory hepatocytes in type 2 diabetes (87). A self-sustaining inflammatory circuit is created when AGEs produced by long-term hyperglycemia bind on renal RAGE receptors to activate NFκB, which transcriptionally upregulates both JAK_2 and IL-6 (88,89). The poor effectiveness of RAS inhibitors alone in stopping the development of DN is likely due to the fact that blocking any one input to this circuit with current monotherapies leaves the others intact (90).

5. Molecular Convergence Nodes (MCNs): A Novel Therapeutic Framework

5.1 Conceptual Basis of MCNs

Systems biology and network pharmacology are the sources of the idea behind Molecular Convergence Nodes (MCNs) (91,92). Certain biological components, such as proteins, transcription factors, or kinases, receive inputs from and disseminate outputs to numerous separate pathogenic pathways in a disease characterized by multiple crossing signaling cascades (93). Because a single pharmacological intervention at an MCN disrupts multiple disease-relevant cascades simultaneously, these convergence nodes can be distinguished from linear pathway components by their high connectivity and potential to produce disproportionately large therapeutic effects when targeted (94).

We propose that $FOXO_1$, $AdipoR_1/R_2$, and JAK/$STAT_3$ satisfy the requirements for MCNs in T2DM (95). Gluconeogenesis, oxidative stress resistance, and mitochondrial quality control are the outputs of $FOXO_1$, which combines inputs from insulin, GLP-1, glucagon, glucocorticoids, and AMPK (96). AdipoR combines inputs and outputs from adiponectin with AMPK, PPARα, and anti-inflammatory signaling in the kidney, muscle, and liver (97). JAK/$STAT_3$ combines inputs from AGEs, leptin, IL-6, and elevated glucose with outputs to inflammation, fibrosis, apoptosis, and EMT in several renal cell types (98).

5.2 Evidence for MCN Connectivity

Crucially, the three suggested MCNs are related to each other (99). AdipoR is linked to $FOXO_1$ suppression because AMPK, which is activated downstream of AdipoR, phosphorylates and activates SIK family kinases, which inhibit $CRTC_2$ and thus lower $FOXO_1$ co-activator activity (100). On the other hand, increased $FOXO_1$ activity in insulin-resistant hepatocytes transcriptionally upregulates SELE and inflammatory cytokine genes, feeding systemic inflammation that activates renal JAK/$STAT_3$ (101). Under inflammatory conditions, $STAT_3$ has been shown to transcriptionally suppress $AdipoR_2$ in hepatocytes, resulting in a negative feedback loop where JAK/$STAT_3$ activation decreases AdipoR-mediated cytoprotection (102).

These connections imply that a medication that can modulate all three MCNs at the same time, such as an AMPK activator that also suppresses $STAT_3$ (as metformin partially does) in combination with an AdipoR agonist and a selective $FOXO_1$ inhibitor, could stop T2DM-related organ damage at several levels at once (103,104). The next stage of T2DM medication research should prioritize the development of such MCN-targeting combo methods (105).

6. Future Research Directions and Clinical Translation

6.1 Biomarker Development Based on MCNs

Clinical tests that measure MCN activity must be created and verified if MCNs are to direct tailored T2DM treatment (106). Functional indicators for FOXO1 might include circulating PEPCK activity and fasting gluconeogenic flow as determined by stable isotope tracer investigations (e.g., $2H_2O$ gluconeogenesis tests) (107). Candidate biomarkers for AdipoR signaling include urine AMPK phosphorylation indicators in exfoliated tubular cells, plasma HMW adiponectin, and adipokine receptor expression in renal biopsy tissues (108). Soluble gp130 levels, urine $STAT_3$ phosphopeptides, and renal biopsy $STAT_3$ immunohistochemistry have demonstrated initial diagnostic usefulness for JAK/$STAT_3$ in inflammatory kidney disorders (109).

6.2 MCN-Targeting Drug Combinations

We suggest the following hypothesis-driven medication combinations for clinical research based on the MCN framework: (1) Adiporon or omega-3-derived AdipoR agonist (AdipoR/AMPK activation) + semaglutide (GLP-1RA, FOXO1 suppression) + baricitinib or low-dose tofacitinib (JAK/$STAT_3$ inhibition) to concurrently target all three MCNs (110–112). (2) mTOR inhibitor (FOXO1 derepression in certain situations) + IL-6 receptor antibody (upstream JAK/$STAT_3$ blocking) + SGLT2 inhibitor (adiponectin upregulation, renal hemodynamic protection) (113,114). To find responder subgroups, these combinations should be evaluated in patient cohorts stratified by biomarkers (115).

6.3 Epigenetic Regulation of MCNs

Epigenetic control is a new but little-studied aspect of MCN biology (116). SIRT1-mediated deacetylation regulates FOXO1 activity, and NAD+ depletion causes SIRT1 levels to decrease with age and type 2 diabetes (117). In inflammatory hepatocytes, DNMT3a has been shown to methylate the AdipoR2 promoter, suppressing adiponectin response (118). In diabetic kidneys, $SOCS_3$ promoter hypermethylation maintains JAK/$STAT_3$ hyperactivity (119). These epigenetic changes indicate that strategies to restore the epigenetic landscape should be used in addition to MCN-targeting pharmacotherapy, such as using DNMT inhibitors to reactivate silenced AdipoR2 and $SOCS_3$ or NAD+ precursors (NMN, NR) to activate SIRT1 and restore FOXO1 acetylation dynamics (120,121).

Discussion

The concept of Molecular Convergence Nodes (MCNs) offers a systems-level framework for understanding the complex molecular architecture of Type 2 Diabetes Mellitus (T2DM) (122,123). Unlike traditional approaches that focus on individual signaling pathways, the MCN model emphasizes highly connected molecular hubs that integrate signals from multiple pathogenic processes. Given that T2DM involves simultaneous disturbances in glucose metabolism, lipid homeostasis, inflammation, oxidative stress, and tissue remodeling, targeting isolated pathways may not adequately address disease progression. MCNs provide a mechanistic explanation for why many single-target therapies improve selected metabolic parameters yet fail to completely prevent long-term organ damage.

Among the proposed MCNs, FOXO1 represents a particularly important regulatory node linking insulin signaling, hepatic glucose production, and metabolic stress responses (124). Persistent FOXO1 activation contributes to excessive gluconeogenesis and hyperglycemia in insulin-resistant states. The phenomenon of selective hepatic insulin resistance further highlights the importance of FOXO1, as gluconeogenic signaling becomes resistant to insulin while lipogenic pathways remain active. This divergence contributes to the coexistence of hyperglycemia and dyslipidemia that characterizes T2DM. The ability of GLP-1 receptor agonists to indirectly suppress FOXO1 activity further supports its central role in metabolic regulation and identifies FOXO1 as a promising therapeutic target (125,126).

AdipoR1 and AdipoR2 constitute a second MCN that connects adipokine signaling with energy metabolism, mitochondrial function, and tissue protection (127). Reduced adiponectin signaling is increasingly recognized as a mechanistic contributor to insulin resistance and diabetic organ injury. Through activation of AMPK and PPARα pathways, AdipoR signaling enhances glucose utilization, promotes fatty acid oxidation, improves mitochondrial function, and suppresses inflammatory responses. In the kidney, AdipoR-mediated signaling protects podocytes, mesangial cells, and tubular epithelial cells from metabolic stress and fibrosis. The observation that therapies such as SGLT2 inhibitors can increase adiponectin levels further suggests that restoration of AdipoR signaling may contribute to their cardiorenal benefits (128).

The JAK/$STAT_3$ pathway serves as a third MCN by integrating inflammatory, metabolic, and fibrotic signals (129). Hyperglycemia, AGEs, oxidative stress, leptin, and inflammatory cytokines all converge on this pathway, promoting renal inflammation, podocyte injury, and tubulointerstitial fibrosis. Sustained activation of JAK/$STAT_3$ contributes to diabetic nephropathy through regulation of genes involved in

extracellular matrix deposition, apoptosis, and inflammatory signaling. The suppression of endogenous negative regulators such as SOCS3 further amplifies pathway activity and may contribute to the persistence of renal injury despite improvements in glycemic control (130).

A major strength of the MCN framework is the recognition that FOXO1, AdipoR signaling, and JAK/STAT3 do not function independently. Instead, these nodes are connected through multiple feedback and feed-forward interactions. AMPK activation downstream of AdipoR signaling can suppress FOXO1 co-activator activity, thereby reducing hepatic gluconeogenesis (131). Conversely, increased FOXO1 activity may enhance inflammatory signaling that contributes to activation of renal JAK/STAT3 pathways (132). Evidence also suggests that inflammatory STAT3 signaling can suppress AdipoR2 expression, reducing adiponectin-mediated cytoprotection (133). These interactions indicate that the three MCNs form a dynamic regulatory network rather than isolated signaling modules.

The existence of this interconnected network has important therapeutic implications. Targeting a single MCN may provide only partial benefit because the remaining nodes can continue to reinforce disease-promoting pathways. Combination approaches designed to simultaneously modulate FOXO1, AdipoR signaling, and JAK/STAT3 activity may therefore produce greater therapeutic effects than monotherapies. This concept mirrors successful network-based treatment strategies used in other complex diseases, including cancer and HIV infection, where simultaneous disruption of multiple interconnected pathways has substantially improved clinical outcomes (134).

An additional dimension of MCN biology is provided by epigenetic regulation. SIRT1-dependent control of FOXO1 activity, DNMT3a-mediated suppression of AdipoR2 expression, and SOCS3 promoter hypermethylation all suggest that epigenetic mechanisms contribute to persistent dysregulation of these signaling nodes (135–137). Such alterations may help explain the phenomenon of metabolic memory, in which the risk of diabetic complications remains elevated despite subsequent improvement in glycemic control (138,139). Consequently, therapeutic strategies aimed at restoring normal epigenetic regulation may complement direct pharmacological targeting of MCNs.

Several limitations of the current framework should be acknowledged. Much of the mechanistic evidence supporting the proposed MCNs originates from animal models and in vitro studies, and further validation in human tissues is required. In addition, the degree to which these signaling networks vary among individuals remains unclear. Genetic variation, environmental influences, microbiome composition, and concurrent therapies may all influence MCN activity and therapeutic responsiveness. Furthermore, the safety and feasibility of long-term combination therapies targeting multiple MCNs will require careful evaluation in clinical studies (140). Despite these limitations, the MCN framework provides a unifying model that integrates diverse aspects of T2DM pathophysiology into a coherent mechanistic network. By identifying FOXO1, AdipoR1/R2, and JAK/STAT3 as highly connected signaling hubs, this approach offers new opportunities for biomarker development, patient stratification, and rational combination therapy design. Future studies should focus on validating MCN activity in human disease, developing reliable biomarkers of node activity, and testing biomarker-guided combination therapies capable of simultaneously targeting multiple disease-driving pathways (141–145).

Conclusion

Molecular Convergence Nodes (MCNs), a unique paradigm for comprehending and addressing the molecular pathophysiology of type 2 diabetes, have been presented in this review (141). By analyzing FOXO1, AdipoR1/R2, and JAK/STAT3 as high-connectivity signaling hubs rather than isolated pathway components, we uncover a landscape of molecular interconnections that explains the systemic nature of organ damage associated with type 2 diabetes and implies the inherent limitations of single-target therapies (142–144).

MCN-based combination treatment can be readily translated into preclinical proof-of-concept studies since the three MCNs suggested here are individually well-validated targets with available pharmacological methods for their regulation (142–144). The creation of clinical biomarkers that can measure MCN activity in specific patients is a significant advancement that allows for sensible patient classification and customized combination medication (145).

In the end, the MCN of nephrology, hepatology, neuroendocrinology, and adipocyte biology around a shared molecular story that has the potential to change type 2 diabetes from a chronic illness that can be managed into a disease that can be prevented and possibly reversed (141,145).

Acknowledgments

The authors acknowledge all researchers whose work contributed to the scientific understanding

summarized in this review. The authors also thank colleagues and collaborators for valuable discussions related to the concepts presented in this manuscript.

Author Contributions

Conceptualization, Literature review, Writing – Original Draft: S Charu Krishna Priya
Writing – Review & Editing: Rishita Bandla
All authors read and approved the final manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were generated or analysed during the current study.

Conflicts of Interest

The authors declare no conflict of interest.

Ethical Approval

Ethical approval was not required because this study is based exclusively on published literature.

Artificial Intelligence Disclosure

Artificial intelligence tools were used solely for language assistance and manuscript preparation support. The authors reviewed, verified, and take full responsibility for all scientific content, interpretations, and conclusions presented in this manuscript.

Abbreviations

T2DM – Type 2 Diabetes Mellitus
FOXO1 – Forkhead Box Protein O1
AMPK – AMP-Activated Protein Kinase
AdipoR – Adiponectin Receptor
JAK – Janus Kinase
STAT3 – Signal Transducer and Activator of Transcription 3
DN – Diabetic Nephropathy
AGE – Advanced Glycation End Product

References

1. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799-806.
2. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
3. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325-338.
4. Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol. 2011;12(3):141-151.
5. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85-96.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
7. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107.
8. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137-188.
9. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-690.
10. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004;117(4):421-426.

11. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 2013;17(2):185-196.
12. Brosius FC, Tuttle KR, Kretzler M. JAK inhibition in the treatment of diabetic kidney disease. Diabetologia. 2016;59(8):1624-1627.
13. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009;25(19):2466-2472.
14. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004;117(4):421-426.
15. Nakae J, Oki M, Cao Y. The FoxO transcription factors and metabolic regulation. FEBS Lett. 2008;582(1):54-67.
16. Matsumoto M, Pocai A, Rossetti L, Depinho RA, Accili D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 2007;6(3):208-216.
17. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction. Nature. 2003;423(6939):550-555.
18. Biggs WH III, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes cytoplasmic sequestration of FKHR1. Proc Natl Acad Sci U S A. 1999;96(13):7421-7426.
19. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85-96.
20. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96(6):857-868.
21. Gross DN, van den Heuvel APJ, Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene. 2008;27(16):2320-2336.
22. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008;7(2):95-96.
23. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852-871.
24. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510(7503):84-91.
25. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, et al. Inhibition of PKCε prevents hepatic insulin resistance. Cell Metab. 2007;6(6):476-485.
26. Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease. Nat Rev Endocrinol. 2008;4(11):589-598.
27. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106(2):171-176.
28. Hagiwara A, Cornu M, Cybulski N, Polak P, Betz C, Trapani F, et al. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt. Cell Metab. 2012;15(5):725-738.
29. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306(5695):457-461.
30. Matsumoto M, Han S, Kitamura T, Accili D. Dual role of FoxO1 in the regulation of hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006;116(9):2464-2472.
31. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756.
32. Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide-1 (GLP-1). Mol Metab. 2019;30:72-130.
33. Holz GG. Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in pancreatic beta cells. Diabetes. 2004;53(1):5-13.
34. Screaton RA, Conkright MD, Katoh Y, Best JL, Canettieri G, Jeffries S, et al. The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell. 2004;119(1):61-74.
35. Dentin R, Liu Y, Koo SH, Hedrick S, Vargas T, Heredia J, et al. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature. 2007;449(7160):366-369.

36. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes. 2008;57(8):2046-2054.
37. Knauf C, Cani PD, Kim DH, Iglesias MA, Chabo C, Waget A, et al. Role of central nervous system glucagon-like peptide-1 receptors in enteric glucose sensing. Diabetes. 2008;57(10):2603-2612.
38. Burcelin R. The gut-brain axis: a major glucoregulatory player. Diabetes Metab. 2010;36(Suppl 3):S54-S58.
39. Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473-4488.
40. Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429.
41. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762-769.
42. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol. 2006;8(5):516-523.
43. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab. 2009;296(1):E22-E36.
44. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332-339.
45. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and metabolic syndrome. J Clin Invest. 2006;116(7):1784-1792.
46. Sharma K. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118(5):1645-1656.
47. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin receptor agonist and healthy life extension. Nature. 2013;503(7477):493-499.
48. Hardie DG. AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels. Annu Rev Nutr. 2014;34:31-55.
49. Deepa SS, Zhou L, Ryu J, Wang C, Mao X, Li C, et al. APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCζ signaling pathway. Mol Endocrinol. 2011;25(10):1773-1785.
50. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262.
51. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf). 2009;196(1):65-80.
52. Viollet B, Guigas B, Leclerc J, Hébrard S, Lantier L, Mounier R, et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism. J Clin Invest. 2009;119(6):1438-1449.
53. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458(7241):1056-1060.
54. Patti ME, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev. 2010;31(3):364-395.
55. Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 2018;14(5):291-312.
56. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89(3):1025-1078.
57. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118(5):1645-1656.
58. Rutkowski JM, Wang ZV, Park AS, Zhang J, Zhang D, Hu MC, et al. Adiponectin promotes functional recovery after podocyte injury. Am J Physiol Renal Physiol. 2013;305(11):F1544-F1555.
59. Fang F, Bae EH, Hu A, Liu GC, Zhou X, Williams V, et al. Deletion of the gene for adiponectin accelerates diabetic nephropathy in mice. Am J Physiol Renal Physiol. 2015;308(11):F1318-F1327.
60. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol. 2007;292(2):F617-F627.

61. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439-451.
62. Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased serum adiponectin levels in patients with type 2 diabetes after SGLT2 inhibitor treatment. J Clin Med Res. 2016;8(4):265-270.
63. Okada-Iwabu M, Iwabu M, Ueki K, Yamauchi T, Kadowaki T. Perspective of small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Diabetes Obes Metab. 2015;17(Suppl 1):74-79.
64. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002;109(Suppl):S121-S131.
65. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(Pt 8):1281-1283.
66. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651-662.
67. Brosius FC III. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord. 2008;9(4):245-254.
68. Lu TC, Wang Z, Feng X, Chuang PY, Fang W, Shen Y, et al. Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney Int. 2009;76(1):63-71.
69. Sun G, Reddy MA, Yuan H, Lanting L, Kato M, Natarajan R. Epigenetic histone methylation modulates fibrotic gene expression. J Biol Chem. 2010;285(51):40163-40172.
70. Goldstein BJ, Mahadev K, Wu X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes. 2005;54(2):311-321.
71. Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010;3(2):101-108.
72. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19(3):433-442.
73. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99(2):342-348.
74. Reiser J, Sever S. Podocyte biology and pathogenesis of kidney disease. Annu Rev Med. 2013;64:357-366.
75. Dai Y, Gu L, Yuan W, Yu Q, Ni Z, Wang X. STAT3 signaling pathway in podocyte apoptosis. Am J Nephrol. 2012;36(2):121-130.
76. He JC, Husain M, Sunamoto M, D'Agati VD, Klotman ME, Iyengar R, et al. Nox4 mediates TGF-β1-induced podocyte apoptosis. J Am Soc Nephrol. 2004;15(7):1691-1702.
77. Dryer SE, Reiser J. TRPC6 channels and kidney disease. Physiology (Bethesda). 2010;25(4):229-240.
78. Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol. 2004;15(Suppl 1):S55-S57.
79. Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol. 2006;151:175-183.
80. Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, et al. Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells. Kidney Int. 1999;56(3):860-872.
81. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991-1006.
82. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest. 2004;34(12):785-796.
83. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7(12):684-696.
84. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429-1437.
85. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112(12):1776-1784.
86. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7(6):327-340.
87. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3):813-823.

88. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl). 2005;83(11):876-886.
89. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108(7):949-955.
90. Tuttle KR. Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol. 2005;16(6):1537-1538.
91. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56-68.
92. Hopkins AL. Network pharmacology. Nat Biotechnol. 2007;25(10):1110-1111.
93. Loscalzo J, Kohane I, Barabási AL. Human disease classification in the postgenomic era. Mol Syst Biol. 2007;3:124.
94. Berger SI, Ma'ayan A, Iyengar R. Systems pharmacology of arrhythmias. Sci Signal. 2010;3(118):ra30.
95. Kitamura T. The role of FOXO1 in β-cell failure and type 2 diabetes mellitus. Nat Rev Endocrinol. 2013;9(10):615-623.
96. Gross DN, Wan M, Birnbaum MJ. The role of FOXO in the regulation of metabolism. Curr Diab Rep. 2009;9(3):208-214.
97. Yamauchi T, Iwabu M, Okada-Iwabu M, Kadowaki T. Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab. 2014;28(1):15-23.
98. Banes-Berceli AK, Al-Azawi H, Proctor D, et al. Angiotensin II and JAK/STAT signaling in diabetic nephropathy. Kidney Int. 2007;72(10):1199-1208.
99. Kitada M, Koya D. Renal protective effects of metformin through AMPK activation. Clin Exp Nephrol. 2013;17(4):469-473.
100. Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 2005;437(7062):1109–1111.
101. Fan W, Imamura T, Sonoda N, Sears DD, Patsouris D, Kim JJ, et al. FOXO1 transrepresses PPARγ transactivation. Cell Metab. 2009;10(6):516–522.
102. Inoue H, Ogawa W, Ozaki M, Haga S, Matsumoto M, Furukawa K, et al. Role of STAT3 in adiponectin receptor regulation and insulin resistance. J Biol Chem. 2004;279(12):11321–11326.
103. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585.
104. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20(6):953–966.
105. Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, et al. The Drug Repurposing Hub. Nat Med. 2017;23(4):405–408.
106. Pearson ER. Personalized medicine in diabetes: the role of biomarkers. Diabetologia. 2019;62(11):1905–1911.
107. Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K, Kalhan SC. Contributions of gluconeogenesis to glucose production in type 2 diabetes mellitus. J Clin Invest. 1996;98(2):378–385.
108. Looker HC, Colombo M, Hess S, Brosnan MJ, Farran B, Dalton RN, et al. Biomarkers of diabetic kidney disease. Diabetologia. 2015;58(8):1664–1674.
109. Garbers C, Hermanns HM, Schaper F, Müller-Newen G, Grötzinger J, Rose-John S, et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012;23(3):85–97.
110. Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013;503(7477):493–499.
111. Wilding JPH. The role of GLP-1 receptor agonists in obesity and diabetes treatment. Lancet Diabetes Endocrinol. 2021;9(11):734–746.
112. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662.
113. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293.
114. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
115. Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507–522.
116. Ling C, Rönn T. Epigenetics in human obesity and type 2 diabetes. Cell Metab. 2019;29(5):1028–1044.
117. Kitada M, Ogura Y, Monno I, Koya D. Sirtuins and type 2 diabetes: role in inflammation, oxidative stress,

and mitochondrial function. Front Endocrinol (Lausanne). 2019;10:187.
118. Sun X, He Y, Ma TT, Huang C, Zhang L, Li J. DNMT3a-mediated epigenetic regulation in metabolic disease. Front Cell Dev Biol. 2021;9:645366.
119. Reddy MA, Zhang E, Natarajan R. Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia. 2015;58(3):443–455.
120. Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513–528.
121. Imai SI, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464–471.
122. Barabási AL. Network medicine—from obesity to the diseasome. N Engl J Med. 2007;357(4):404–407.
123. Loscalzo J, Barabási AL. Systems biology and the future of medicine. Wiley Interdiscip Rev Syst Biol Med. 2011;3(6):619–627.
124. Accili D. Insulin action research and the future of diabetes treatment: the 2017 Banting Medal for Scientific Achievement Lecture. Diabetes. 2018;67(9):1701–1709.
125. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15–30.
126. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–223.
127. Yamauchi T, Iwabu M, Okada-Iwabu M, Kadowaki T. Adiponectin receptors and obesity. Handb Exp Pharmacol. 2019;251:47–75.
128. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes. Lancet. 2019;393(10166):31–39.
129. Tuttle KR, Brosius FC, Adler SG, Kretzler M, Mehta RL, Tumlin JA, et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease. Nephrol Dial Transplant. 2018;33(11):1950–1959.
130. Ortiz-Muñoz G, Lopez-Parra V, Lopez-Franco O, Fernandez-Vizarra P, Mallavia B, Flores C, et al. Suppressors of cytokine signaling in diabetic nephropathy. J Am Soc Nephrol. 2010;21(5):763–772.
131. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011;13(9):1016–1023.
132. Fan W, Morinaga H, Kim JJ, Bae E, Spann NJ, Heinz S, et al. FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages. EMBO J. 2010;29(24):4223–4236.
133. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–783.
134. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679–692.
135. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303(5666):2011–2015.
136. Ling C, Del Guerra S, Lupi R, Rönn T, Granhall C, Luthman H, et al. Epigenetic regulation of genes involved in insulin secretion and action. Diabetes. 2008;57(5):1149–1154.
137. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol. 2010;299(1):F14–F25.
138. Nathan DM, Cleary PA, Backlund JYC, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653.
139. Holman RR, Paul SK, Bethel MA, Neil HAW, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359(15):1565–1576.
140. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.
141. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011;8(3):184–187.
142. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
143. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes. Lancet. 2014;383(9922):1068–1083.
144. Forbes JM, Thorburn DR. Mitochondrial dysfunction and diabetic complications. Nat Rev Endocrinol. 2018;14(5):291–312.
145. Ashley EA. The precision medicine initiative: a new national effort. JAMA. 2015;313(21):2119–2120.